Clinical trials
Resectable Lung Non-Small Cell Carcinoma clinical trials
Below are recruiting resectable lung non-small cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 187 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05487391RecruitingPhase 3
QL1706 plus chemo after lung cancer surgery
This trial studies whether a study drug called QL1706 added to standard platinum chemotherapy can lower the chance of lung cancer coming back after surgery. It targets people with stage II to IIIB non-small cell lung cancer who have had their tumor fully removed.
ShanghaiAges 18 years+ - NCT05498428RecruitingPhase 2
Amivantamab for advanced lung cancer with EGFR mutations
This Phase 2 study tests amivantamab (an antibody medicine) in people with advanced or metastatic non-small cell lung cancer that has specific EGFR gene changes. It may help shrink tumors or control cancer when standard curative treatments aren’t possible.
La Jolla, CaliforniaAges 18 years+ - NCT05502523Recruiting
Blood test DNA levels after lung surgery
This study looks at how different lung surgical techniques affect levels of tumor DNA in the blood before and after surgery for early-stage lung cancer. It may help doctors choose surgical approaches and use a blood test to monitor cancer after surgery.
Abington, PennsylvaniaAges 18 years+ - NCT05672108RecruitingPhase 2
Chemo delivered into lung tumors using a catheter
This trial studies a treatment that delivers chemotherapy directly to lung tumors by placing a catheter into lung blood vessels. It may help people with lung cancer or lung metastases that are growing despite standard treatment, or who cannot tolerate it.
Duarte, CaliforniaAges 18 years+ - NCT05742607RecruitingPhase 2
Durvalumab plus IPH5201 before lung surgery for early cancer
This phase 2 study tests durvalumab plus IPH5201 given before surgery to improve outcomes for people with resectable non-small cell lung cancer. It aims to shrink or control the cancer and make surgery more effective, using information about specific tumor markers like PD-L1.
St. Petersburg, FloridaAges 18 years+ - NCT05751018RecruitingPhase 2
Pyrotinib for first treatment of HER2-mutated lung cancer
This Phase 2 trial studies pyrotinib as a first (initial) anti-cancer treatment for advanced lung cancer that has specific HER2 changes. It aims to shrink tumors and control the cancer, especially in people whose test results show HER2 insertion mutation, point mutation, or amplification.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05751798RecruitingPhase 1/Phase 2
Test drug OSE-279 for advanced lung cancer that has no key mutations
This Phase 1/2 study tests how well and how safely OSE-279 works in people with advanced non-small cell lung cancer (NSCLC) who cannot be cured with surgery or radiation. It also looks at the right dose and how it may help, especially if the tumor has high PD-L1.
AnderlechtAges 18 years+ - NCT05789082RecruitingPhase 1/Phase 2
Divarasib for untreated lung cancer with KRAS G12C
This trial studies divarasib to see if it is safe and can shrink or control advanced lung cancer. Participants must have a KRAS G12C mutation and have not had prior treatment for their advanced disease.
Duarte, CaliforniaAges 18 years+ - NCT05830058RecruitingPhase 2
PET-guided focused radiation for limited worsening lung, melanoma, kidney cancer
This Phase 2 study tests whether using a PET scan to guide focused radiation (SBRT) can control a small number of cancer spots that are starting to grow despite prior treatment. It may help patients avoid wider radiation by targeting only the limited progressing areas.
Duarte, CaliforniaAges 18 years+ - NCT05979818RecruitingPhase 1
Propranolol plus immunotherapy and chemo for advanced lung cancer
This trial tests adding a beta-blocker (propranolol) to a combination of immunotherapy (sintilimab) and standard chemotherapy for people with advanced non-small cell lung cancer that hasn't been treated before. The goal is to see if this new triple treatment helps shrink tumors better than chemo-immunotherapy alone.
Changsha, HunanAges 18–75 - NCT05985655RecruitingPhase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors
This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT05997719Recruiting
Study of EGFR-mutated lung cancer evolution and markers
This study looks at how EGFR-mutated lung cancer changes over time and tries to find markers that can predict how well you might respond to treatment. You will provide a tumor sample for genetic analysis.
GuanzhouAges 18 years+ - NCT06041776RecruitingPhase 3
Befotertinib after surgery for early-stage lung cancer with EGFR mutation
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
BeijingAges 18 years+ - NCT06053099Recruiting
Study of osimertinib after surgery for EGFR-mutated lung cancer
This trial collects data from people with early-stage lung cancer that has a common EGFR mutation. After complete surgical removal of the tumor, participants take osimertinib for 3 years and are followed regularly to see how well the treatment works and why resistance might develop.
AngersAges 18 years+ - NCT06057766Recruiting
Physical activity coaching after lung cancer surgery
This trial tests a coaching program to help you become more physically active after surgery for early-stage lung cancer. It may help you recover and improve your well-being.
Genk, LimburgAges 18 years+ - NCT06077760RecruitingPhase 3
Personalized cancer vaccine plus Keytruda for lung cancer after surgery
This study tests a new personalized cancer vaccine (V940) plus Keytruda versus a placebo plus Keytruda for people with non-small cell lung cancer that was removed by surgery. The goal is to see if the vaccine helps prevent the cancer from coming back.
Anchorage, AlaskaAges 18 years+ - NCT06080776RecruitingPhase 3
SH-1028 vs placebo for early-stage EGFR-mutated lung cancer
This trial tests a pill called SH-1028 (an EGFR-targeted drug) versus a placebo to see if it helps prevent lung cancer from coming back after surgery in people with EGFR-mutated NSCLC. You may be eligible if you had complete removal of stage II-IIIB NSCLC and your tumor has a specific EGFR mutation.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06090266RecruitingPhase 1/Phase 2
Study of OR502 alone and with other cancer treatments
This trial tests an experimental drug called OR502, which targets a protein on immune cells, to see if it can help fight advanced solid tumors. It is given alone or with other anti-cancer drugs, and the study aims to find the best dose and see how well it works.
Austin, TexasAges 18 years+ - NCT06102057RecruitingPhase 2
PET-guided small volume chemoradiation with immunotherapy for lung cancer
This trial tests a new combination of chemotherapy, radiation, and immunotherapy (durvalumab) for people with stage III non-small cell lung cancer that cannot be removed with surgery. The goal is to see if giving a smaller, more focused radiation dose can be just as effective with fewer side effects.
DresdenAges 18 years+ - NCT06120283RecruitingPhase 1
Testing a new drug for breast cancer and other solid tumors
This trial tests a new oral drug (BGB-43395) alone or with other treatments for people with advanced breast cancer or other solid tumors that depend on CDK4. It aims to find safe doses and see if the drug helps shrink tumors or slow growth.
Denver, ColoradoAges 18 years+ - NCT06123754RecruitingPhase 3
Envafolimab plus chemo for stage III NSCLC before surgery
This trial tests a new immunotherapy (Envafolimab) combined with standard chemotherapy before and after surgery for stage III non-small cell lung cancer that can be removed. The goal is to see if adding Envafolimab helps shrink the tumor and improve outcomes compared to chemotherapy alone.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06192849RecruitingPhase 2
Furmonertinib after surgery for EGFR 20 insertion lung cancer
This trial tests a targeted pill (furmonertinib) to prevent your lung cancer from coming back after surgery. It is for people with a certain genetic change in their tumor (EGFR exon 20 insertion) and stage IB, II, or IIIA disease.
Chengdu, SichuanAges 18 years+ - NCT06222489RecruitingPhase 2
HER3 PET scan for advanced EGFR-mutant lung cancer
This study uses a special PET/CT scan to measure a protein called HER3 in your tumors. The scan uses a radioactive version of the drug patritumab deruxtecan (HER3-DXd). This test may help doctors understand how much HER3 is in your cancer and decide if HER3-targeted therapy could work for you.
Amsterdam, North HollandAges 18 years+ - NCT06241807RecruitingPhase 2
Camrelizumab plus chemo before surgery for stage III lung cancer
This trial tests adding the immunotherapy drug camrelizumab to standard chemotherapy before surgery for people with stage IIIA-IIIB non-small cell lung cancer. The goal is to see if this combination shrinks tumors more effectively before removal.
Jinan, ShandongAges 18–75
Hear when a new Resectable Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for resectable lung non-small cell carcinoma?
- Yes. Clin2 currently lists 187 recruiting resectable lung non-small cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a resectable lung non-small cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a resectable lung non-small cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.